FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Full prescribing information for Lifyorli will be posted on Drugs@FDA.

Efficacy and Safety

Efficacy was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, trial in 381 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required. The trial excluded patients who required chronic or frequent use of glucocorticoids. Patients were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.

The major efficacy outcome measures were progression-free survival (PFS) assessed by blinded independent central review according to RECIST version 1.1 and overall survival (OS). Median PFS was 6.5 months (95% CI: 5.6, 7.4) in the relacorilant in combination with nab-paclitaxel arm and 5.5 months (95% CI: 3.9, 5.9) in the nab-paclitaxel arm (Hazard ratio 0.70 [95% CI: 0.54, 0.91]; two-sided p-value 0.0076). Median OS was 16 months (95% CI: 13, 18.3) in the relacorilant in combination with nab-paclitaxel arm and 11.9 months (95% CI: 10, 13.8) in the nab-paclitaxel arm (Hazard ratio 0.65 [95% CI: 0.51, 0.83]; two-sided p-value 0.0004).

The prescribing information includes a contraindication for patients who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity. The most common adverse reactions (incidence ≥ 20%), including laboratory abnormalities, that occurred in patients treated with relacorilant in combination with nab-paclitaxel were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

Recommended Dosage

The recommended dosage of relacorilant is 150 mg orally once on the day before, the day of, and the day after each nab-paclitaxel infusion until disease progression or unacceptable toxicity. The recommended dosage for nab-paclitaxel is 80 mg/m2 administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

This review used the Assessment Aid, a voluntary submission from the Applicant to facilitate the FDA’s assessment. The FDA approved this application 3.5 months ahead of the FDA goal date.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.

eierstokkanker, Relacorilant, Nab-paclitaxel, chemoresistent, FDA, fase 3 studie Rosella

---

• FDA keurt Relacorilant plus Nab-Paclitaxel goed voor chemoresistente eierstokkanker op basis van de resultaten uit de fase 3 Rosella studie

---

• Chemotherapie met AN-152 and AN-207 remt sterk de groei van vergevorderde kanker vanuit endometriose - baarmoederkanker met LHRH receptoren. copy 1

---

• Overzichtstudie van effecten en kosten van verschillende chemokuren bij recidieven van eierstokkanker.

---

• Chemo combinatie van cisplatin en oraal etoposide voor eierstokkanker  zou betere resultaten geven aldus Nederlandse onderzoekers

---

• Eribuline mesylate geeft significant betere resultaten op ziektevrije tijd bij patienten met eierstokkanker welke niet resistent zijn tegen platinum chemo's

---

• Taxol wordt afgeraden bij eierstokkanker na zesjarige studie onder meer dan 2000 vrouwen. Ook arts-bioloog drs. E. Valstar stelt na studie analyse dat taxol bij eierstokkanker als eerste lijns afgeschaft zou moeten worden.

---

• Wekelijkse chemospoelingen van de buikholte als postoperatieve behandeling verlengt levensduur bij eierstokkankerpatiënten met stadium III en IV.

---

• Topotecan geeft in fase III studie geen enkele meerwaarde, zelfs kortere tijd tot recidief, na operatie toegediend bij eierstokkankerpatiënten stadium III en IV tegenover carboplatin - paclitaxel.

---

• Chemo bij eierstokkanker: een overzicht van recente ontwikkelingen en belangrijke studie abstracten en artikelen.